Ruxolitinib for the Treatment of T-Cell Large Granular Lymphocytic Leukemia

• Status: Not yet recruiting
• Trial end date: 2025-12-31
• Target enrollment: 0
• Participant gender: All

Summary

This phase II trial tests whether ruxolitinib works to shrink tumors in patients with T-cell large granular lymphocyte leukemia. Ruxolitinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ohio State University Comprehensive Cancer Center
• Treatments: Janus Kinase Inhibitors

Criteria

Inclusion Criteria:

• Age 18 or older

• Diagnosis of T-LGLL defined as: CD3+CD8+ cell population > 650/mm^3 or CD3+CD8+CD57+ population > 500/mm^3 and the presence of a clonal T-cell receptor (within 1 month of diagnosis). Note: patients with MDS-like T-LGLL may be included with PI approval even if CD3+CD8+ cell population is < 650/mm^3, though +TCR is required. Natural-Killer (NK) LGL is also permitted, provided there is a clonal NK-cell population noted with > 500 cells/mm^3

• Untreated T-LGLL

• Failed at least one line of frontline therapy; off treatment for at least 14 days or 5 half-lives, whichever is longer

• Require Treatment for T-LGLL (one or more required)

• Symptomatic anemia with hemoglobin < 10 g/dL

• Transfusion-dependent anemia

• Neutropenia with absolute neutrophil count (ANC) < 500/mm^3

• Neutropenia with ANC < 1500/mm^3 with recurrent infections

• Platelet count > 50 x 10^9/L

• Serum creatinine =< 2 x the upper limit of normal (ULN)

• Total bilirubin =< 1.5 x ULN (patients with Gilbert's syndrome with a bilirubin > 1.5 x ULN permitted)

• Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 1.5 x ULN

• Eastern cooperative oncology group (ECOG) performance status =< 2

• Men and women of reproductive potential must agree to follow accepted birth control methods for the duration of the study. Female subject is either post-menopausal or surgically sterilized or willing to use an acceptable method of birth control (i.e., a hormonal contraceptive, intra-uterine device, diaphragm with spermicide, condom with spermicide, or abstinence) for the duration of the study. Male subject agrees to use an acceptable method for contraception for the duration of the study

• Able to sign informed consent

Exclusion Criteria:

• Absolute neutrophil count (ANC) less than 100/mm^3

• Active infection requiring ongoing anti-microbial treatment. Patients with human immunodeficiency virus (HIV), positive hepatitis B surface antigen or hepatitis C antibody will be excluded

• Concurrent immune-suppressive therapy (prednisone or equivalent up to 20 mg permitted to treat T-LGL symptoms, but must be weaned within one month of initiation of trial drug). Patients on stable, chronic prednisone =< 10 mg for rheumatologic/autoimmune conditions are exempted from this requirement. They may enroll on the study

• Active, concurrent malignancy unless deemed related to T-LGLL by principal investigator (PI). Early stage skin cancers, prostate cancer, permitted if under no active therapy

• Positive pregnancy test

• Platelet count < 50,000/uL

• Unstable angina or myocardial infarction within the past 2 months

• Chronic obstructive pulmonary disease or other interstitial lung disease in active exacerbation

• Serum alanine transaminase (ALT), aspartate transaminase (AST), total bilirubin, or alkaline phosphatase > 1.5 x upper limit of normal (ULN) (unless document Gilbert's)

• Estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73 m^2 using the Modification of Diet in Renal Disease (MDRD) equation